Treatment of the African-American patient with congestive heart failure

Current Treatment Options in Cardiovascular Medicine

Volumn 7, Issue 4, 2005, Pages 307-315

  Kamath, Sandeep A ^a   Yancy, Clyde W ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CANDESARTAN; CARVEDILOL; CLONIDINE; CREATININE; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDRALAZINE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; ISOSORBIDE DINITRATE; LISINOPRIL; LOSARTAN; METOPROLOL SUCCINATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; POTASSIUM SPARING DIURETIC AGENT; SPIRONOLACTONE; VERAPAMIL;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AFRICAN AMERICAN; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ASTHMATIC STATE; BRADYCARDIA; BRONCHOSPASM; CLINICAL PROTOCOL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; COUGHING; DEPRESSION; DISEASE COURSE; DIZZINESS; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENTIATION; DYSPNEA; EVIDENCE BASED MEDICINE; FATIGUE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY FAILURE; LIVER TOXICITY; LUNG EDEMA; META ANALYSIS; NEUTROPENIA; PANCREATITIS; PERIPHERAL EDEMA; REVIEW; SEXUAL DYSFUNCTION; STEVENS JOHNSON SYNDROME; SURVIVAL; SYSTEMATIC REVIEW;

EID: 27544499575     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-005-0041-z     Document Type: Review

References (41)

1. American Heart Association: African Americans and Cardiovascular Diseases Statistics Fact Sheet. Dallas, TX: American Heart Association; 2004.
2. Packer M, Coats AJ, Fowler MB, et al.: Effect of carvediolol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651-1658.
3. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS]. The CONSENSUS Trial Study Group [no authors listed]. N Engl J Med 1987, 316:1429-1443.
4. Hunt SA, Baker DW, Chin MH, et al.: ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report from the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2001, 38:2101-2113.
5. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality of patients with severe heart failure. N Engl J Med 1999, 341:709-717.
6. Pitt B, Remme WJ, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
7. Bardy GH, Lee KL, Mark DB, et al.: Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005, 352:225-237.
8. Cohn JN, Tognoni G: A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667-1675.
9. Yancy CW: Heart failure in African Americans: a cardiovascular enigma. J Card Fail 2000, 6:183-186.
10. Dries DL, Exner DV, Gersch BK, et al.: Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 1999, 340:609-616.
11. Saunders E: Hypertension in minorities: blacks. Am J Hypertens 1995, 8(12 pt 2):115S-119S.
12. Flack JM, Ferdinand KC, Nasser SA: Epidemiology of hypertension and cardiovascular disease in African Americans. J Clin Hypertens 2003, 5(1 suppl 1):5-11.
13. Gillum RF: The epidemiology of cardiovascular disease in black Americans. N Engl J Med 1996, 335:1597-1598.
14. Rahman M, Douglas JG, Wright JT: Pathophysiology and treatment implications of hypertension in the African American population. Endocrinol Metab Clin North Am 1997, 26:125-144.
15. Levy D: Left ventricular hypertrophy risk. In Hypertension Primer. Edited by Izzo JL, et al. Dallas, TX: American Heart Association; 2003:243-246.
16. Turner ST, Schwartz GL, Chapman AB, et al.: C825T polymorphism of the G protein beta-3 subunit and antihypertensive response to a thiazide diuretic. Hypertension 2001, 37:739-743.
17. August P: TGF Beta-1 overexpressed in African American hypertensives. Proc Natl Acad Sci U S A 2000, 97:3479-3484.
18. McNamara DM, Holubkov R, Janosko K, et al.: Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 2001, 103:1644-1648.
19. Small KM, Wagoner LE, Levin AM, et al.: Synergistic polymorphisms of beta 1 and alpha 2c adrenergic receptors and the risk of congestive heart failure. N Engl J Med 2002, 347:1135-1142.
20. Mason DA, Moore JD, Green SA: A gain of function polymorphism in a G-protein coupling domain of the human beta-1 adrenergic receptor. J Biol Chem 1999, 274:12670-12674.
21. Cohn JN, Archibald DG, Ziesche S, et al.: Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986, 314:1547-1552.
22. Cohn JN, Johnson G, Ziesche S, et al.: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991, 325:303-310.
23. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators [no authors listed]. N Engl J Med 1991, 325:293-302.
24. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators [no authors listed]. N Engl J Med 1992, 327:685-691.
25. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. The Beta-Blocker Evaluation of Survival Trial (BEST) Investigators [no authors listed]. N Engl J Med 2001, 344:1659-1667.
26. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001-2007.
27. Packer M, Bristow MR, Cohn JN, et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996, 334:1349-1355.
28. Carson P, Fowler MB, Mohacsi P, et al.: Effect of carvedilol in black patients with severe heart failure: results of the COPERNICUS study [abstract]. Circulation 2001, 104:II-754.
29. Exner DV, Dries DL, Domanski MJ, et al.: Lesser response to angiotensin-converting enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001, 344:1351-1357.
30. Dries DL, Strong MH, Cooper RS, et al.: Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. J Am Coll Cardiol 2002, 40:311-317.
31. Bourassa MG, Gurne O, Bangdiwala SI, et al.: Natural history and patterns of current practice in heart failure. J Am Coll Cardiol 1993, 22:14A-19A.
32. Shekelle PG, Rich MW, Morton SC, et al.: Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular dysfunction according to race, gender, and diabetic status. A meta-analysis of major clinical trials. J Am Coll Cardiol 2003, 41:1529-1538.
33. Andreka P, Aiyar N, Olson LC, et al.: Bucindolol displays intrinsic sympathomimetic activity in human myocardium. Circulation 2002, 105:2429-2434.
34. Yancy CW, Fowler MB, Colucci WS, et al.: Race and the response to adrenergic blockade with carvedilol in patients with heart failure. N Engl J Med 2001, 344:1358-1365.
35. Pfeffer MA, Swedberg K, Granger CB, et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003, 362:759-766.
36. Cohn JN, Tognoni G: A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667-1675.
37. Pitt B, Poole-Wilson PA, Segal R, et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000, 355:1582-1587.
38. Carson P, Ziesche S, Johnson G, et al.: Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 1999, 5:178-187.
39. Taylor AL, Ziesche S, Yancy C, et al.: Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004, 351:2049-2057.
40. Levine GM, Keaney JF, Vita JA: Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med 1995, 332:512-521.
41. Kalinowski L, Dobrucki I, Malinski T: Race-specific differences in endothelial function: predisposition of African Americans to vascular disease. Circulation 2004, 109:2511-2517.